Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Dr. Skoulidis on Combining Chemotherapy and Immunotherapy in NSCLC

Ferdinandos Skoulidis, MD, PhD, MRCP
Published: Friday, Nov 10, 2017



Ferdinandos Skoulidis, MD, PhD, MRCP, assistant professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses combining chemotherapy and immunotherapy in non–small cell lung cancer (NSCLC).

The KEYNOTE-021 data suggested a combination of pembrolizumab (Keytruda) with carboplatin/pemetrexed was associated with a 55% objective response rate, almost more than a chemotherapy doublet alone.

Combining chemotherapy with immunotherapy benefited PD-L1–negative tumors and has an additive effect, so it would be a valid treatment option for patients who express low levels of PD-L1, explains Skoulidis.
SELECTED
LANGUAGE


Ferdinandos Skoulidis, MD, PhD, MRCP, assistant professor, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses combining chemotherapy and immunotherapy in non–small cell lung cancer (NSCLC).

The KEYNOTE-021 data suggested a combination of pembrolizumab (Keytruda) with carboplatin/pemetrexed was associated with a 55% objective response rate, almost more than a chemotherapy doublet alone.

Combining chemotherapy with immunotherapy benefited PD-L1–negative tumors and has an additive effect, so it would be a valid treatment option for patients who express low levels of PD-L1, explains Skoulidis.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x